Lenalidomid Stada (Lenalidomide)

Lenalidomide is employed in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow.

• Multiple myeloma: improves disease control and prolongs progression‑free survival.
• Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves blood counts.
• Relapsed or refractory multiple myeloma after prior therapy: enhances overall response rates.

• Lenalidomide binds to the cereblon component of the CRL4^CRBN E3 ubiquitin ligase complex, altering its substrate specificity. This triggers ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), producing anti‑angiogenic, immunomodulatory, and anti‑proliferative effects. The downstream response includes heightened natural‑killer cell activity, inhibition of pro‑inflammatory cytokines, and disruption of the tumor microenvironment.

Lenalidomid Stada may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Neutropenia: reduced neutrophil count.
• Thrombocytopenia: lowered platelet levels.
• Fatigue: persistent tiredness.
• Diarrhea: loose stools.
• Nausea: upset stomach.
• Rash: skin irritation.

Serious or Rare Side Effects

• Venous thromboembolism: blood clots in veins.
• Severe neutropenia: markedly low neutrophils increasing infection risk.
• Severe thrombocytopenia: dangerous bleeding risk.
• Secondary primary malignancies: emergence of new cancers.
• Severe allergic reactions: anaphylaxis or hypersensitivity.
• Hepatic failure: liver dysfunction.

Before initiating Lenalidomid Stada, several safety considerations should be reviewed.

• Pregnancy: contraindicated; teratogenic risk (Category X).
• Thrombosis risk: assess patient history and consider prophylactic anticoagulation.
• Hematologic monitoring: perform regular complete blood counts.
• Renal impairment: evaluate kidney function and adjust dose if needed.
• Drug interactions: review concomitant medications for potential effects.
• Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomid Stada can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce drug exposure.
• Anticoagulants (e.g., warfarin): increased risk of bleeding.
• Live vaccines: reduced vaccine effectiveness and possible infection.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase lenalidomide levels.
• NSAIDs (e.g., ibuprofen, naproxen): may exacerbate renal toxicity.
• Diuretics (e.g., furosemide): may affect electrolyte balance and kidney function.
• Immunosuppressants (e.g., cyclosporine): potential additive hematologic toxicity.
• Hormonal contraceptives: may have reduced efficacy; advise alternative contraception.